Latest Boardroom Shifts News

Spenda Limited (ASX: SPX) has voluntarily suspended trading of its shares from 2 June 2026 to manage disclosure around its institutional accelerated renounceable entitlement offer (AREO). The suspension is expected to last until 10 June or until the AREO results are announced.

Bison Resources has appointed Tim Mackellar as CEO, leveraging his senior mining and capital markets experience to drive exploration and development efforts.

Little Green Pharma (ASX:LGP) has completed its merger with Cannatrek, creating a dominant player in Australia and Europe’s medicinal cannabis market with a majority stake held by former Cannatrek shareholders.

ARC Funds Limited has secured $600,000 through a share placement priced at a 33% premium to its last traded price, aiming to strengthen its working capital and support growth initiatives.

Raiz Invest announces a leadership change with Brendan Malone stepping down as CEO and Craig Keary taking over, signalling a new chapter for the fintech amid steady growth.

Trek Metals has marked a breakthrough year with a high-grade manganese discovery at its Christmas Creek Project in Western Australia, supported by strong assay results and expanded exploration tenure. The company bolstered its balance sheet with $19.5 million raised to fund drilling and further exploration.

Third Age Health Services posted a 17.9% revenue increase and 24.7% profit rise for FY26, driven by strategic acquisitions and expansion in aged residential care services.

PolyNovo has completed its pivotal US clinical trial report for NovoSorb BTM and adjusted its FDA Premarket Approval submission timeline to late 2026 to incorporate updated regulatory requirements and additional data.

TradeWindow reported a 20% rise in FY26 revenue to NZ$9.6 million with annual recurring revenue surpassing NZ$10 million. The company narrowed its EBITDA loss and is targeting breakeven in FY27 while advancing its AI-driven FreightAI platform.

VRX Silica has kicked off a $6.23 million renounceable entitlement offer, underwritten to $2 million, to fund key development activities at its Arrowsmith North silica sand project including a strategic property purchase and engineering works.

Select Harvests delivered a 33% rise in underlying NPAT despite a wet harvest and higher costs, announcing a fully franked interim dividend and a 10% on-market share buy-back.

Australian Clinical Labs appoints Greg Horan as Group CEO effective August 2026, marking a leadership transition after a decade under Melinda McGrath. Horan’s healthcare and operational expertise positions ACL for its next growth phase.